Company news
Racura Oncology Ltd (ASX:RAC) news
Racura Oncology Ltd news releases on 6ix. Latest, Jun 26, 2024: RC220 GLP Non-clinical Toxicology Program Successful
Press releases — page 2
RC220 GLP Non-clinical Toxicology Program Successful
June 25, 2024
Race Appoints George Clinical for Phase 1 Trial of RC220
June 19, 2024
FDA RPD Designation Granted for RC220 Bisantrene
June 17, 2024
Bisantrene Highly Active in a Multiple Myeloma Mouse Model
June 12, 2024
US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
June 10, 2024
Bisantrene with Decitabine Enhances Cancer Cell Killing
May 13, 2024
Quarterly Activity Report & Appendix 4C
April 18, 2024
RC220 cGMP Manufacturing Complete
March 25, 2024
Bisantrene shows potent anticancer activity in AML models
March 5, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
Race Receives $4.0m R&D Tax Refund for Financial Year 2023
February 27, 2024
December 2023 Preclinical & Clinical Program Update
December 29, 2023
Bonus Options Prospectus
November 21, 2023
Updated Strategy and Investor Presentation
November 21, 2023
Dr Daniel Tillett appointed CEO of Race Oncology
November 21, 2023
RC220 Meets Quality Specifications
November 8, 2023
Impressive Bisantrene Phase 2 AML Clinical Results
November 6, 2023
Trading Halt
November 2, 2023
RC220 Peripheral Infusion Safety Confirmed
October 16, 2023
RC220 Toxicology and Safety Pharmacology Studies Initiated
October 4, 2023
Bisantrene cGMP API Manufacturing Completed at Laurus Labs
September 26, 2023
Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
September 20, 2023
Race Board and Management Team Changes
August 21, 2023
Race Strategic Update August 2023
August 8, 2023
Race Receives Additional $1.66m R&D Tax Refund for FY 2022
July 13, 2023
Race executes agreement with Ardena for GMP manufacturing
July 11, 2023
Race global agreement with City of Hope to access FTO IP
July 9, 2023
H1 2023 Preclinical and Clinical Programs Update
July 6, 2023
Letter to Shareholders
June 15, 2023
Race releases complete cardio-protection data & video
April 13, 2023
Race releases cardioprotection market potential data
April 3, 2023
Race Receives $1.48m R&D Tax Refund for Financial Year 2022
March 27, 2023
Race Leadership Changes
March 23, 2023
Pause in Trading
March 21, 2023
Race Executes Contracts to Commence Breast Cancer Trial
March 12, 2023
New Collaboration to Understand Zantrene Cardioprotection
March 2, 2023
Race Receives Cardioprotection Ethics Trial Approval
January 31, 2023
Race supports Study of Extramedullary AML
December 22, 2022
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
December 15, 2022
Race Appoints Damian Clarke-Bruce as CEO & Managing Director
December 13, 2022
Positive Pre-IND Guidance from FDA on Zantrene
November 22, 2022
Response to ASX Price Query
October 18, 2022
Race Develops Improved IV Formulation of Zantrene
September 27, 2022
Race Initiates New Drug Discovery Program
September 26, 2022
Race Oncology : Update - Notification of buy-back - RAC
July 27, 2022
Race Oncology : RAC Quarterly Investor Presentation
July 27, 2022
Race Oncology : Quarterly Activity Report & Appendix 4C
July 21, 2022
Zantrene Protects Mouse Hearts from Chemotherapy Damage
June 29, 2022
Zantrene shows synergy with kinase inhibitors in melanoma
June 27, 2022
Zantrene Improves Immune Therapy Treatment of Melanoma
June 21, 2022